Annual Report

Overview

The report describes the company's 2024 focus on advancing tasquinimod studies in myelofibrosis and multiple myeloma, alongside continued laquinimod development. Its sustainability section emphasizes limited environmental impact, resource responsibility, waste handling and employee well-being. Financially, the Group recorded no sales during the year and reported an operating loss of SEK 39.8 M.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Publication date: 4 April 2025
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services